1.
Rev Neurol (Paris)
; 178(5): 460-471, 2022 May.
Article
in English
| MEDLINE
| ID: mdl-35562199
ABSTRACT
The two commonest groups of neurodegenerative disorders causing movement disorders are synucleinopathies and tauopathies. These disorders are characterised by the accumulation of abnormally misfolded forms of α-synuclein and tau proteins. Our current understanding of their pathogenesis suggests that extracellular forms of these proteins are of major relevance to the mechanism of pathology propagation throughout the brain and disease progression. The most novel approaches to find disease-modifying therapies aim to reduce or block these forms of tau and α-synuclein. This article reviews therapeutic strategies targeting α-synuclein and tau protein which have entered clinical development.
Subject(s)
Movement Disorders , Neurodegenerative Diseases , Tauopathies , Humans , Movement Disorders/therapy , Neurodegenerative Diseases/therapy , Tauopathies/pathology , Tauopathies/therapy , alpha-Synuclein , tau Proteins/metabolism
2.
Neurología (Barc., Ed. impr.)
; 35(9): 703-705, nov.-dic. 2020. ilus
Article
in Spanish
| IBECS
| ID: ibc-192761
ABSTRACT
No disponible
Subject(s)
Humans , Male , Adult , Coronavirus Infections/complications , Pneumonia, Viral/complications , Pandemics , Status Epilepticus/virology , Autism Spectrum Disorder , Intellectual Disability
3.
Neurologia (Engl Ed)
; 35(9): 703-705, 2020.
Article
in English, Spanish
| MEDLINE
| ID: mdl-32893073
Subject(s)
Autism Spectrum Disorder/virology , COVID-19/complications , Status Epilepticus/virology , Adult , Autism Spectrum Disorder/physiopathology , Azithromycin/therapeutic use , COVID-19/diagnosis , COVID-19/physiopathology , Heparin, Low-Molecular-Weight/therapeutic use , Humans , Hydroxychloroquine/therapeutic use , Intellectual Disability , Male , Methylprednisolone/therapeutic use , Pandemics , SARS-CoV-2/drug effects , Status Epilepticus/physiopathology , COVID-19 Drug Treatment
4.